Related Experiment Videos
Lethal cardiovascular complications in patients receiving bromocriptine for ablactation
1Department of Obstetrics and Gynecology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, USA.
Medicine and Law
|January 1, 1995
Summary
Bromocriptine mesylate (Parlodel) use for lactation suppression is linked to lethal circulatory collapse. Pregnancy-induced hypertension may increase risks of severe side effects like vasospasm.
Area of Science:
- Pharmacology
- Obstetrics
- Toxicology
Background:
- Bromocriptine mesylate is widely used for lactation suppression (ablactation) postpartum.
- Severe adverse events, including fatalities, have been associated with its use.
Observation:
- Three cases of lethal circulatory collapse in women using bromocriptine for lactation suppression are reported.
- These cases were identified through medicolegal inquiries, highlighting the value of malpractice reviews.
Findings:
- The adverse events suggest bromocriptine mesylate may cause severe side effects, expanding its known risk profile.
- Pregnancy-induced hypertension appears to be a risk factor for severe untoward effects from bromocriptine.
- Vasospasm, a paradoxical reaction to bromocriptine's vasodilatory effects, is the likely common mechanism for these side effects.
Implications:
- Clinicians should be aware of the potential for severe cardiovascular events, particularly in hypertensive postpartum patients.
- Further research into the risks and benefits of bromocriptine for lactation suppression is warranted.
- Medicolegal case reviews can identify rare but critical adverse drug reactions.